On June 25, 2024, the Board of Directors (the “Board”) of McCormick & Company, Incorporated (“McCormick”) appointed Marcos Gabriel as Executive Vice President and Chief Financial Officer of McCormick effective December 1, 2024.
Timothy Brown will step down as interim Chief Financial Officer of HP Inc. (“HP”) effective upon HP’s appointment of a new Chief Financial Officer on August 5, 2024, as disclosed below.
Departed
Winthrop Watson
President and Chief Executive Officer
Federal Home Loan Bank of Pittsburgh
Effective
2024-12-31
Successor
David G. Paulson
Filed
June 26, 2024, 7:59 PM ET
On June 24, 2024, Winthrop Watson, President and Chief Executive Officer (CEO) of the Federal Home Loan Bank of Pittsburgh (Bank), notified the Bank’s Board of Directors (Board) that he intends to retire from the Bank, effective December 31, 2024.
Appointed
David G. Paulson
President and Chief Executive Officer
Federal Home Loan Bank of Pittsburgh
Effective
2024-12-31
Filed
June 26, 2024, 7:59 PM ET
The Board has named David G. Paulson as President and CEO, effective upon Mr. Watson’s retirement.
Appointed
Edward Dulac
Executive Vice President and Chief Financial Officer
the Company announced the appointment, effective July 22, 2024 (“Start Date”), of Edward Dulac to serve as Executive Vice President and Chief Financial Officer (“CFO”), treasurer and principal financial officer of the Company.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 21, 2024, William J. Fehrman, the President and Chief Executive Officer of Centuri Holdings, Inc. (the “Company”), informed the Company’s Board of Directors (the “Board”) of his decision to resign as President and Chief Executive Officer, effective July 31, 2024.
Until a permanent successor is identified, the Company has appointed Paul J. Caudill to serve as the Company’s interim Chief Executive Officer, effective July 31, 2024.
Dr. Jordan Plews, notified the board of directors of the Company (the “Board”) of his intention to resign as chief executive officer of the Company , effective on the close of business on June 21, 2024.
On June 24, 2024, Jennings "Jay" Walker, Executive Vice President and Chief Financial Officer of Capital Bancorp, Inc. (the "Company") and its banking subsidiary, Capital Bank, N.A. (the "Bank"), informed the Company and the Bank of his decision to resign, effective August 1, 2024.
the existing officers and directors of the Company, Mr. James Owens, Mr. Michael Hendrickson, Mr. Sanford Simon, Mr. Don Roberts and Ms. Adrienne Anderson have either resigned or been voted out of their positions.
On June 26, 2024, the Company announced that Gary Corona, currently Senior Vice President, Global Financial Planning and Analysis, has been appointed to serve as interim Chief Financial Officer (Interim CFO) of the Company, effective upon Ms. Parkhill’s departure.
Departed
Karen L. Parkhill
Executive Vice President and Chief Financial Officer
On June 21, 2024, Karen L. Parkhill, Executive Vice President and Chief Financial Officer of Medtronic plc (Company), notified the Company of her decision to resign from the Company, effective August 2, 2024.
the Company and Ken Rizvi (who previously served as the Company’s CFO and who had resigned effective as of June 30, 2024, as reported by the Company in its Current Report on Form 8-K filed on May 14, 2024) mutually agreed that Mr. Rizvi’s resignation would instead take effect immediately prior to the effectiveness of Mr. Olmstead’s appointment.
On June 25, 2024, the Board of Directors (the “Board”) of SMART Global Holdings, Inc. (the “Company”) appointed Nathan Olmstead as the Company’s Senior Vice President and Chief Financial Officer (“CFO”), effective as of June 26, 2024 (the “Start Date”).
Mr. Nihill succeeds Michael J. McDermott who retired as Chief Financial Officer and Treasurer of the Company, Rhinebeck Bancorp, MHC and the Bank, effective May 31, 2024
On June 25, 2024, Methode Electronics, Inc. (the “Company” or “Methode”) announced the appointment of Jon DeGaynor as the Company’s new President and Chief Executive Officer, starting July 15, 2024.
Mr. DeGaynor will replace Kevin Nystrom, who has served as Interim Chief Executive Officer since May 7, 2024.
Appointed
Dr. Hj Mazlan Hj Bin Ahmad
Chief Executive Officer
QMIS TBS Capital Group Corp.
Effective
2024-06-24
Filed
June 25, 2024, 7:59 PM ET
the Company’s Board of Directors had appointed Dr Hj Mazlan Hj Bin Ahmad to serve as the Company’s Chief Executive Officer, effective immediately.
Role change
Dr. Chin Yung Kong
Chief Executive Officer
QMIS TBS Capital Group Corp.
Effective
2024-06-24
Successor
Dr. Hj Mazlan Hj Bin Ahmad
Filed
June 25, 2024, 7:59 PM ET
Dr. Chin Yung Kong, one of the founders and a long-time officer of the Company, had chosen to resign as Chief Executive Officer of the Company, effective immediately.
Christopher S. Sotos informed Clearway Energy, Inc. (the “Company”) on April 30, 2024 that, effective as of June 30, 2024, he will move on from his position as President and Chief Executive Officer of the Company and resign from his role as a member of the Board of Directors (the “Board”) of the Company.
the following officers resigned: Daniel Jones, President, Chief Executive Officer and Chairman, and Francis Scully, Chief Financial Officer and Security
On June 19, 2024, Brianna Gerber, the Chief Financial Officer and Chief Accounting Officer of ChromaDex Corporation (the “Company”), informed the Company that she will be resigning from her roles with the Company, effective July 12, 2024 (the “Separation Date”).
Effective July 1, 2024, Mr. Guillot will return to his role as Senior Vice President – Operations and Chief Operating Officer upon the appointment of Jennifer L. Slater as President and Chief Executive Officer, as previously disclosed by the Company in its Current Report on Form 8-K filed on June 14, 2024.
Departed
Michael Byrnes
Chief Financial Officer and Secretary
eFFECTOR Therapeutics, Inc.
Effective
2024-06-21
Successor
Craig R. Jalbert
Filed
June 24, 2024, 7:59 PM ET
On June 21, 2024, Stephen T. Worland, Ph.D., President and CEO, Michael Byrnes, Chief Financial Officer and Secretary, and Douglas Warner, M.D., Chief Medical Officer, ceased serving in their respective officer positions.
Appointed
Craig R. Jalbert
CEO, President, Treasurer and Secretary
eFFECTOR Therapeutics, Inc.
Effective
2024-06-21
Filed
June 24, 2024, 7:59 PM ET
On June 21, 2024, the Board appointed Craig R. Jalbert, age 62, as the Company’s CEO, President, Treasurer and Secretary, and sole member of the Board.
Departed
Stephen T. Worland, Ph.D.
President and CEO
eFFECTOR Therapeutics, Inc.
Effective
2024-06-21
Successor
Craig R. Jalbert
Filed
June 24, 2024, 7:59 PM ET
On June 21, 2024, Stephen T. Worland, Ph.D., President and CEO, Michael Byrnes, Chief Financial Officer and Secretary, and Douglas Warner, M.D., Chief Medical Officer, ceased serving in their respective officer positions.
Appointed
John M. McCaffery
Executive Vice President and Chief Financial Officer
the Board of Directors had appointed John M. McCaffery as Executive Vice President and Chief Financial Officer of the Company, and its wholly owned subsidiary, Wayne Bank (the “Bank”), effective as of June 24, 2024.
Departed
Alexander J. Bruni
Executive Vice President & Chief Financial Officer
Alexander J. Bruni, the Company’s Executive Vice President & Chief Financial Officer, has, at the request of the Company, resigned from his position as an officer of the Company, effective June 21, 2024.
Jonathan A. Leon, the Company’s Senior Vice President, Corporate Treasurer, has been appointed as interim Chief Financial Officer effective June 21, 2024.
the Board also announced that Christopher H. Bohnert has been appointed to fill the newly-created vacancy of Senior Vice President, Chief Financial Officer, effective as of the Transition Date.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.